The United States Food and Drug Administration (FDA) has granted approval to AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, for its RINVOQ (upadacitinib), a 15mg, once-daily oral Janus kinase (JAK) inhibitor, it was reported on Friday.
The product is intended for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It is likely to be offered in the United States in late August 2019.
The approval of the product is supported by data from the SELECT program, one of the largest Phase 3 programs in rheumatoid arthritis with around 4,400 patients assessed across all treatment arms in five studies. The studies cover evaluations of efficacy, safety and tolerability across a variety of rheumatoid arthritis patients, including those who failed or were intolerant to biologic disease-modifying anti-rheumatic drugs and who were naïve or inadequate responders to methotrexate. The product is not indicated for methotrexate-naive patients.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML